Before a medicinal product for human use is authorised for placing on the market of one or more Member States, it generally has to undergo extensive studies to ensure that it is safe, of high quality and effective for use in the target population. The rules and procedures for obtaining a marketing authorisation are laid down in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive 2004/27/EC (OJ L 136, 30.4.2004, p. 34).] and in Regulation (EC) No 726/2004.
Recital 1, Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…
In forcesince 29 Mar 2006cited 1×
Arrêt du Tribunal (huitième chambre) du 2 mars 2022. Debregeas et associés Pharma (D & A Pharma) contre Commission européenne et Agence euroDecision
Ainsi qu’il ressort des considérants 1 à 3 du règlement n o 507/2006 : « Avant d’obtenir l’[AMM] dans un ou plusieurs États membres, un médicament à usage humain doit généralement faire l’objet d’études approfondies …
2 Mar 2022 · 62020TJ0556